A newly released study indicated that childhood peanut allergies could be desensitized with oral immunotherapy treatments, and some children could achieve remission.

The clinical trial was co-led by Arkansas Children’s Research Institute (ACRI) and UAMS researcher Stacie Jones, M.D. The results were published Jan. 21 in the medical journal The Lancet.

The youngest trial participants and those who started with lower levels of peanut-specific antibodies were the most likely to be successful.

“In children with a peanut allergy, initiation of peanut oral immunotherapy before age 4 years was associated with an increase in both desensitization and remission,” according to The Lancet’s summary. “Development of remission correlated with immunological biomarkers. The outcomes suggest a window of opportunity at a young age for intervention to induce remission of peanut allergy.”

ACRI, a research institute owned by Arkansas Children’s Hospital, was one of five participating U.S. academic medical centers in the clinical trial. The study was funded by the National Institutes of Health.

The trial involved 146 children who received peanut oral immunotherapy treatments or placebos between Aug. 13, 2013, and Oct. 1, 2015.

Read the full story on the Talk Business & Politics website.